Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ibrexafungerp - SCYNEXIS

Next Previous
X
Search
Drug Profile

Ibrexafungerp - SCYNEXIS

Alternative Names: Brexafemme; GSK 5458448; Ibrexafungerp citrate; MK-3118; SCY 078; SCY-078-citrate

Latest Information Update: 01 Oct 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co; SCYNEXIS
  • Developer Jiangsu Hansoh Pharmaceutical; Merck & Co; SCYNEXIS
  • Class Alkanes; Amines; Antifungals; Carboxylic acids; Ethers; Glycosides; Heterocyclic compounds; Pyridines; Small molecules; Triazoles; Triterpenes
  • Mechanism of Action Beta-1,3-D glucan synthetase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Invasive bronchopulmonary aspergillosis; Invasive candidiasis
  • New Molecular Entity Yes
  • Available For Licensing Yes - Vulvovaginal candidiasis

Highest Development Phases

  • Marketed Vulvovaginal candidiasis
  • Phase III Candidiasis; Invasive candidiasis
  • Phase II Invasive bronchopulmonary aspergillosis
  • Preclinical Mycoses
  • No development reported Pneumocystis pneumonia; Unspecified

Most Recent Events

  • 25 Sep 2024 Phase-I clinical trials in Vulvovaginal candidiasis (In adolescents) in Mauritius (PO) (EudraCT2024-000382-25)
  • 09 Aug 2024 Scynexis terminates the phase II SCYNERGIA trial in Invasive bronchopulmonary aspergillosis in USA, Australia, Belgium, Canada, Mexico, South Africa, Germany as enrollment took longer than anticipated (slow enrollment during COVID) before August 2024 (NCT03672292)
  • 08 Aug 2024 SCYNEXIS plans to re-start the phase-III MARIO trial for Invasive candidiasis (PO),

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top